Alan Parsa, MD
Basic profileAlan Parsa is an Endocrinology/Metabolic physician affiliated with University of Hawaiʻi at Mānoa. OpenAlex indexes 64 publications with 2,050 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli LillyProgram year202512 paymentsResearch$892,738
- AbbVieProgram year202510 paymentsResearch$134,422
- Corcept TherapeuticsProgram year202555 payments$74,692
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
69.3%GLP-1 receptor agonist22.6%Ozempic51%Trulicity31%Rybelsus9%Mounjaro5%Victoza 3-Pak5%Part D<11 patientsInsulin Analog15.8%Lantus Solostar25%Tresiba Flextouch U-10020%Novolog Flexpen19%Humalog Kwikpen U-10016%Toujeo Max Solostar9%Basaglar Kwikpen U-1008%Tresiba Flextouch U-2005%Part D<11 patients+ 9 more classes in this area
Hormonal (systemic)
17.3%l-Thyroxine11.6%Levothyroxine Sodium90%Synthroid10%Part D≥109 patientsThyroid Hormone Synthesis Inhibitor2.9%Methimazole100%Part D≥37 patients+ 3 more classes in this area
Cardiovascular
6.2%Statin1.9%Atorvastatin Calcium55%Simvastatin25%Rosuvastatin Calcium20%Part D<11 patientsNonsteroidal Mineralocorticoid-Receptor Antagonist1.7%Kerendia100%Part D≥13 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Preventing Amputation Neuromas with Autogenous Vein Grafting
Journal of Surgery Research and Practice
2026 - Fluorescein Dye-Assisted Tangential Excision and Skin Grafting in Hand Burns: Achieving Optimal Cosmetic and Functional Outcomes.
PubMed
2025 - Unexpected Ischemia: A Case of Neonatal Ulcer After Umbilical Artery Catheter Calcium Gluconate Infusion
Plastic & Reconstructive Surgery Global Open
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Cecilia Shikuma, MD
University of Hawaiʻi at Mānoa
Marian Melish, MD
University of Hawaiʻi at Mānoa
Ferdinand Hui, MD
University of Hawaiʻi at Mānoa
Todd Seto, MD
University of Hawaiʻi at Mānoa
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”